NA
CRNX icon

NewEdge Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

NewEdge Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38
Closed -$1.38K – 4230
2026
Q1 		$1.38K Buy
+38
New +$1.7K ﹤0.01% 3863
2024
Q3 		– Sell
-30
Closed -$1.34K – 3841
2024
Q2 		$1.34K Buy
+30
New +$1.39K ﹤0.01% 3409
2023
Q2 		– Sell
-60
Closed -$964 – 3512
2023
Q1 		$964 Hold
60
– – ﹤0.01% 3159
2022
Q4 		$1 Buy
+60
New +$1.06K ﹤0.01% 3992

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NewEdge Advisors's CRNX Position: Q2 2026 in Review

NewEdge Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 38 shares — an estimated $1.38K sold.

NewEdge Advisors first reported a position in CRNX in Q4 2022 and held it in 4 quarters. The position peaked at $1.38K in Q1 2026. 185 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • NewEdge Advisors reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • NewEdge Advisors sold 38 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.38K.
  • NewEdge Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • NewEdge Advisors's Crinetics Pharmaceuticals position peaked at $1.38K in Q1 2026.
  • 185 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.